Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. (Q38444246)

3 September 2017

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. (English)

1 reference

3 September 2017

0 references

Peter Andersen

11

0 references

Else Marie Agger

1

object named as

Else Marie Agger

1 reference

3 September 2017

Ida Rosenkrands

2

1 reference

3 September 2017

Anja Weinreich Olsen

3

1 reference

3 September 2017

Graham Hatch

4

1 reference

3 September 2017

Ann Williams

5

1 reference

3 September 2017

Constantia Kritsch

6

1 reference

3 September 2017

Karen Lingnau

7

1 reference

3 September 2017

Alexander von Gabain

8

1 reference

3 September 2017

Claire Swetman Andersen

9

1 reference

3 September 2017

Karen Smith Korsholm

10

1 reference

3 September 2017

language of work or name

English

0 references

publication date

17 April 2006

1 reference

3 September 2017

1 reference

3 September 2017

24

1 reference

3 September 2017

26

1 reference

3 September 2017

5452-5460

1 reference

Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model

3 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Modulating vaccine responses with dendritic cells and Toll-like receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Separation and quantification of a novel two-component vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Is IgG2a a good Th1 marker in mice?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

The physiology and pathogenicity of Mycobacterium tuberculosis grown under controlled conditions in a defined medium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Freund's complete adjuvant: an effective but disagreeable formula

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Role of Toll-like receptors in costimulating cytotoxic T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

CpG-DNA aided cross-presentation of soluble antigens by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.072

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.03.072

1 reference

3 September 2017

1 reference